Your browser doesn't support javascript.
loading
PRSS contributes to cetuximab resistance in colorectal cancer.
Tan, Zhaoli; Gao, Lihua; Wang, Yan; Yin, Huihui; Xi, Yongyi; Wu, Xiaojie; Shao, Yong; Qiu, Weiyi; Du, Peng; Shen, Wenlong; Fu, Ling; Jia, Ru; Zhao, Chuanhua; Zhang, Yun; Zhao, Zhihu; Sun, Zhiwei; Chen, Hongxing; Hu, Xianwen; Xu, Jianming; Wang, Youliang.
Afiliação
  • Tan Z; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Gao L; Department of Gastrointestinal Oncology, the Fifth Medical Center, General Hospital of PLA, Beijing, China.
  • Wang Y; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Yin H; Department of Gastrointestinal Oncology, the Fifth Medical Center, General Hospital of PLA, Beijing, China.
  • Xi Y; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Wu X; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Shao Y; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Qiu W; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Du P; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Shen W; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Fu L; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Jia R; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Zhao C; Department of Gastrointestinal Oncology, the Fifth Medical Center, General Hospital of PLA, Beijing, China.
  • Zhang Y; Department of Gastrointestinal Oncology, the Fifth Medical Center, General Hospital of PLA, Beijing, China.
  • Zhao Z; Department of Gastrointestinal Oncology, the Fifth Medical Center, General Hospital of PLA, Beijing, China.
  • Sun Z; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Chen H; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Hu X; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Xu J; Beijing Institute of Biotechnology, 20 Dongdajie, Beijing, China.
  • Wang Y; Department of Gastrointestinal Oncology, the Fifth Medical Center, General Hospital of PLA, Beijing, China.
Sci Adv ; 6(1): eaax5576, 2020 01.
Article em En | MEDLINE | ID: mdl-31911942
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tripsina / Neoplasias Colorretais / Inibidor da Tripsina Pancreática de Kazal / Cetuximab Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tripsina / Neoplasias Colorretais / Inibidor da Tripsina Pancreática de Kazal / Cetuximab Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article